



## **atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update**

August 1, 2022

NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and business update on Monday, August 15, 2022.

A video interview with atai management will be available at 8:30 a.m. (ET) at <https://vimeo.com/atailifesciences>. The archived video interview will be available in the "Events" section of the atai website at <https://www.atai.life/>.

### **About atai Life Sciences**

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

atai's business model combines funding, technology, scientific, and regulatory expertise with a focus on innovative compounds, including psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit <https://www.atai.life/>.

### **Contact Information**

*Investor Contact:*

Greg Weaver  
Chief Financial Officer  
Email: [IR@atai.life](mailto:IR@atai.life)

*Media Contact:*

Allan Malievsky  
Senior Director, External Affairs  
Email: [allan@atai.life](mailto:allan@atai.life)